The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- EPS Goes Public, First Listed CRO in Japan
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -4-
June 4, 2001
- BUSINESS NEWS IN BRIEF
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -5-
June 4, 2001
- JACDS Makes Proposals for Nursing Care Business at Drugstores
June 4, 2001
- Wholesalers' Profits Plummet due to Tough Negotiation on Price
June 4, 2001
- Fujisawa Licenses Osteoporosis Drug from Servier
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -1-
June 4, 2001
- Shionogi to Launch MS Contin in Small Packages
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -2-
June 4, 2001
- Takeda to Increase OTC Sales to \100 Bil. in 2005
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -3-
June 4, 2001
- Efco, Kyuyukai to Merge in Fall
June 4, 2001
- Continuing Growth by Focusing on Specialty Pharmaceuticals: Mr Pyott of Allergan
June 4, 2001
- Takiya Shoji, Drux to Merge in August
June 4, 2001
- Listing of 14 Active Ingredients Including Radicut, Zyprexa Approved
June 4, 2001
- Taisho Terminates Business with Daikoku Group
June 4, 2001
- Peak-time Sales of Radicut, Zyprexa Expected to Top \10 Bil.
June 4, 2001
- NEW PRODUCTS NEWS IN BRIEF
June 4, 2001
- Chuikyo to Review NHI Pricing Rule
June 4, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…